 |
|
|
|
|
|
|
|
 |
Results for 'Cancer Vaccines Fantasy or Future?' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Global Vaccine Market Forecast to 2012
|
October 2008 |
£1370 |
42.5 % |
Chinese Markets for Vaccines
|
March 2006 |
£1985 |
35 % |
Global Vaccine Market Outlook (2007-2010)
|
June 2007 |
£1095 |
34.65 % |
Cancer Vaccines: Aim and Shoot
|
May 2008 |
£1780 |
34.5 % |
Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis
3rd Edition
|
November 2008 |
£2735 |
33.6 % |
New Drug Futures: Vaccines Chapter
|
May 2006 |
£695 |
32.55 % |
Vaccines
The World Market
|
February 2007 |
£2735 |
31.85 % |
Vaccines: The World Market
|
February 2007 |
£2735 |
31.85 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
31.15 % |
Analytical Tool: Competitive Outlook on Cancer Vaccines
|
May 2007 |
£2830 |
31 % |
Cancer Vaccine Developments to 2011
|
September 2007 |
£1296 |
29.4 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
28.7 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1495 |
26.95 % |
Global Cancer Treatment Forecast to 2012
|
August 2008 |
£545 |
25.9 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£3150 |
25.2 % |
Biotechnology and Biopharmaceuticals
Transforming Proteins and Genes into Drugs
|
July 2003 |
£55.95 |
24.5 % |
Global Vaccines Market 2008-2023, The
|
August 2008 |
£1499 |
24.15 % |
Cancer Cell Therapy Markets
|
March 2008 |
£2325 |
23.45 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£3150 |
21.7 % |
Health for All? Agriculture and Nutrition, Bioindustry and Environment
Analyses and Recommendations, 3 Volumes
|
November 2005 |
£70 |
21 % |
Immunomodulators
Therapeutic Needs, Pipelines & Prospects
|
August 2007 |
£1495 |
20.3 % |
Pipeline And Commercial Insight
Pediatric And Adolescent Vaccines
|
July 2007 |
£8000 |
19.95 % |
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts:
The Challenge Of Turning Technology Into Therapy
|
July 2007 |
£1999 |
18.2 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£4720 |
18 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4515 |
17.5 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£6340 |
17.15 % |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
|
December 2006 |
£2005 |
17.15 % |
Development and Commercialisation of Protein Therapeutics
Technologies, pipelines and forecasts
|
September 2004 |
£1045 |
16.8 % |
Wyeth Prospects to 2010
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
16 % |
Antiviral Therapeutics
Technologies, Markets and Companies
|
December 2008 |
£1915 |
15.75 % |
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
|
July 2008 |
£3800 |
15.05 % |
Animal Biotechnology
Technologies, Markets and Companies
|
December 2008 |
£1710 |
15.05 % |
Cancer Therapeutics
Market Insight and R&D Pipeline Analysis
|
August 2008 |
£2395 |
14.7 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£3150 |
14.35 % |
Oncology Market Leaders
Analyses and Outlook, Market Report 2008 - 2023
|
October 2008 |
£1499 |
14 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
December 2008 |
£2055 |
13.3 % |
Transdermal Drug Delivery
Technologies, Markets, and Companies
|
December 2008 |
£1710 |
13.3 % |
New Drug Futures
|
May 2006 |
£2995 |
12.5 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£3320 |
12.25 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
12.25 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
11.55 % |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2005 |
11.2 % |
Global Smoking Cessation Market Analysis & Forecasts
Preparing For The First Blockbuster
|
July 2007 |
£1499 |
11.2 % |
Gene Therapy
Technologies, Markets and Companies
|
December 2008 |
£2735 |
11 % |
Personalized Medicine
scientific & commercial aspects
|
December 2008 |
£2735 |
10.85 % |
Therapeutic Proteins
|
February 2005 |
£1999 |
10.5 % |
Angiogenesis Modulators
|
January 2008 |
£1915 |
10.5 % |
Stem Cell Research
|
January 2008 |
£2910 |
10.5 % |
Cell Therapy
Technologies, Markets and Companies
|
December 2008 |
£3080 |
10.15 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
10 % |
What's Hot in Cancer Drug R&D?
|
July 2006 |
£295 |
9.8 % |
Companion Animal Health Products: New edition
|
January 2006 |
£795 |
9.5 % |
Research & Development in the Pharmaceutical Industry
Options for success
|
February 2004 |
£825 |
9.1 % |
5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production
A Study of Biotherapeutic Developers and Contract Manufacturing Organizations, 2007
|
April 2008 |
£1090 |
8.5 % |
Cell Therapy Markets
|
July 2007 |
£2325 |
8.4 % |
Breast Cancer Drug Discoveries
What the future holds 2008
|
December 2008 |
£795 |
8.05 % |
Pipeline Insight: Hepatitis C
Protease inhibitors to drive market expansion
|
June 2006 |
£6495 |
7.35 % |
World Market for Molecular Diagnostics, The
|
January 2009 |
£2735 |
7.35 % |
Medical Nanotechnology Markets
|
September 2008 |
£2325 |
7 % |
Pfizer
Market Outlook for a Global Leader, 2008-2013
|
August 2008 |
£1499 |
6.3 % |
Proteomics
Technologies, Markets and Companies
|
December 2008 |
£2395 |
6.3 % |
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity
R&D Strategies
|
August 2007 |
£7600 |
6.3 % |
Antiageing and Life Enhancement Pharmacotherapeutics
|
January 2006 |
£4600 |
5.6 % |
DNA Sequencing
|
February 2008 |
£3080 |
5.6 % |
Live-Licensing & In-life Testing
R&D Processes and Regulation for New Drugs, 2008-2020
|
January 2008 |
£1499 |
5.6 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
December 2008 |
£1915 |
5.6 % |
Clinical Trials Business; The
|
August 2006 |
£3320 |
4.9 % |
In Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
4.9 % |
Drug Delivery in Central Nervous System Diseases
technologies,markets and companies
|
December 2008 |
£1710 |
4.9 % |
In-Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
4.9 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£290 |
4.55 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£290 |
4.2 % |
|
|
|
|
